Suppr超能文献

18F-氟代胸苷摄取与滤泡性淋巴瘤和易错 DNA 修复。

18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.

机构信息

Department of Haematology, VU University Medical Center (VUMC), De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.

出版信息

EJNMMI Res. 2014 Jan 8;4(1):3. doi: 10.1186/2191-219X-4-3.

Abstract

BACKGROUND

We observed a disproportional 18 F-fluorothymidine (F-FLT) uptake in follicular lymphoma (FL) relative to its low cell proliferation. We tested the hypothesis that the 'excess' uptake of 18 F-FLT in FL is related to error-prone DNA repair and investigated whether this also contributes to 18 F-FLT uptake in diffuse large B cell lymphoma (DLBCL).

METHODS

We performed immunohistochemical stainings to assess the pure DNA replication marker MIB-1 as well as markers of both DNA replication and repair like PCNA, TK-1 and RPA1 on lymph node biopsies of 27 FLs and 35 DLBCLs. In 7 FL and 15 DLBCL patients, 18 F-FLT-PET had been performed.

RESULTS

18 F-FLT uptake was lower in FL than in DLBCL (median SUVmax 5.7 vs. 8.9, p = 0,004), but the ratio of 18 F-FLT-SUVmax to percentage of MIB-1 positive cells was significantly higher in FL compared with DLBCL (p = 0.001). The median percentage of MIB-1 positive cells was 10% (range, 10% to 20%) in FL and 70% (40% to 80%) in DLBCL. In contrast, the median percentages of PCNA, TK-1 and RPA1 positive cells were 90% (range, 80 to 100), 90% (80 to 100) and 100% (80 to 100) in FL versus 90% (60 to 100), 90% (60 to 100) and 100% (80 to 100) in DLBCL, respectively.

CONCLUSIONS

This is the first demonstration of a striking discordance between 18 F-FLT uptake in FL and tumour cell proliferation. High expression of DNA replication and repair markers compared with the pure proliferation marker MIB-1 in FL suggests that this discordance might be due to error-prone DNA repair. While DNA repair-related 18 F-FLT uptake considerably contributes to 18 F-FLT uptake in FL, its contribution to 18 F-FLT uptake in highly proliferative DLBCL is small. This apparently high contribution of DNA repair to the 18 F-FLT signal in FL may hamper studies where 18 F-FLT is used to assess response to cytostatic therapy or to distinguish between FL and transformed lymphoma.

摘要

背景

我们观察到滤泡性淋巴瘤(FL)中 18F-氟代胸腺嘧啶(F-FLT)的摄取不成比例,而其细胞增殖率较低。我们检验了这样一个假设,即 FL 中 18F-FLT 的“过量”摄取与易错 DNA 修复有关,并研究了这种情况是否也导致弥漫性大 B 细胞淋巴瘤(DLBCL)中 18F-FLT 的摄取增加。

方法

我们对 27 例 FL 和 35 例 DLBCL 的淋巴结活检进行了免疫组化染色,以评估纯 DNA 复制标志物 MIB-1 以及 PCNA、TK-1 和 RPA1 等 DNA 复制和修复标志物。在 7 例 FL 和 15 例 DLBCL 患者中进行了 18F-FLT-PET。

结果

FL 中 18F-FLT 的摄取低于 DLBCL(SUVmax 中位数 5.7 比 8.9,p=0.004),但 FL 中 18F-FLT-SUVmax 与 MIB-1 阳性细胞百分比的比值明显高于 DLBCL(p=0.001)。FL 中 MIB-1 阳性细胞的中位数为 10%(范围 10%20%),DLBCL 中为 70%(40%80%)。相比之下,FL 中 PCNA、TK-1 和 RPA1 阳性细胞的中位数分别为 90%(范围 80%100)、90%(80%100)和 100%(80%100),DLBCL 中为 90%(60%100)、90%(60%100)和 100%(80%100)。

结论

这是首次证明 FL 中 18F-FLT 的摄取与肿瘤细胞增殖之间存在显著差异。FL 中与纯增殖标志物 MIB-1 相比,高表达 DNA 复制和修复标志物表明,这种差异可能是由于易错 DNA 修复所致。虽然与 DNA 修复相关的 18F-FLT 摄取对 FL 中 18F-FLT 的摄取有很大贡献,但对高度增殖的 DLBCL 中 18F-FLT 的摄取贡献较小。FL 中 DNA 修复对 18F-FLT 信号的高贡献可能会阻碍使用 18F-FLT 来评估细胞毒性治疗反应或区分 FL 和转化性淋巴瘤的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ad/3895783/3808b91992c1/2191-219X-4-3-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验